Get the Stockscreener App
0.993
1.68%
-0.017
After Hours:
1.01
0.017
+1.71%
Cytomx Therapeutics Inc stock is traded at $0.993, with a volume of 698.39K.
It is down -1.68% in the last 24 hours and down -13.65% over the past month.
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
See More
Previous Close:
$1.01
Open:
$0.99
24h Volume:
698.39K
Relative Volume:
1.00
Market Cap:
$78.11M
Revenue:
$101.21M
Net Income/Loss:
$-569.00K
P/E Ratio:
-1.1821
EPS:
-0.84
Net Cash Flow:
$-56.88M
1W Performance:
-0.60%
1M Performance:
-13.65%
6M Performance:
-77.58%
1Y Performance:
-21.19%
1-Day Range:
$0.99
$1.01
1-Week Range:
$0.9886
$1.07
52-Week Range:
$0.9882
$5.85
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Name
Cytomx Therapeutics Inc
Sector
Industry
Phone
650.515.3185
Address
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| May-09-24 | Upgrade | Wedbush | Neutral → Outperform |
| May-06-24 | Upgrade | Jefferies | Hold → Buy |
| Apr-22-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-14-22 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jul-07-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-07-22 | Downgrade | Mizuho | Buy → Neutral |
| Jul-07-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-22 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-18-22 | Upgrade | Barclays | Underweight → Overweight |
| Nov-15-21 | Initiated | BTIG Research | Buy |
| May-28-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-29-21 | Initiated | JP Morgan | Overweight |
| Mar-23-21 | Upgrade | Jefferies | Hold → Buy |
| Sep-22-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-01-20 | Downgrade | Jefferies | Buy → Hold |
| May-14-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-24-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-04-20 | Initiated | Barclays | Equal Weight |
| Nov-20-19 | Initiated | Guggenheim | Buy |
| Nov-11-19 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-13-19 | Initiated | Mizuho | Buy |
| May-14-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Nov-26-18 | Initiated | Piper Jaffray | Overweight |
| Oct-15-18 | Initiated | Goldman | Neutral |
| Sep-13-18 | Initiated | H.C. Wainwright | Buy |
| Jun-01-18 | Initiated | SunTrust | Buy |
| Jan-05-18 | Initiated | Citigroup | Buy |
| Sep-08-17 | Initiated | Wedbush | Outperform |
| Mar-27-17 | Initiated | H.C. Wainwright | Buy |
| Mar-02-17 | Initiated | Instinet | Buy |
| Jan-03-17 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-02-15 | Initiated | Oppenheimer | Outperform |
View All
Cytomx Therapeutics Inc Stock (CTMX) Latest News
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World
CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday - MarketBeat
CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times
Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - MarketBeat
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues - Simply Wall St
CytomX stock plunges to 52-week low at $1.03 amid market challenges - Investing.com India
CytomX stock plunges to 52-week low at $1.03 amid market challenges By Investing.com - Investing.com South Africa
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in September - MarketBeat
CytomX Therapeutics Inc (CTMX) rating upgrades by Piper Sandler - Knox Daily
Trading Day Triumph: CytomX Therapeutics Inc (CTMX) Ends at 1.09, a -5.22 Surge/Plunge - The Dwinnex
CTMX Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
Squarepoint Ops LLC Has $243,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Selling Buzz: CytomX Therapeutics Inc [CTMX] Chief Business Officer Landau Jeffrey B sells 4,181 shares of the company – Knox Daily - Knox Daily
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
There is no way CytomX Therapeutics Inc (CTMX) can keep these numbers up - SETE News
Forefront Analytics LLC Has $78,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Wall Street SWOT: CytomX Therapeutics stock shows promise amid clinical trials - Investing.com
CytomX Therapeutics Inc [NASDAQ: CTMX] Sees Increase in Stock Value - Knox Daily
Investors in cash trouble should check out CytomX Therapeutics Inc (CTMX) - SETE News
Is it possible to buy CytomX Therapeutics Inc(CTMX) shares at a good price now? - US Post News
Metastatic Cancer Drugs Market Outlook, Insights, and Size: 2024-2033 - WhaTech
CTMX stock rated an Overweight by Piper Sandler - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing CytomX Therapeutics Inc (CTMX)’s Performance - The Dwinnex
Altamira Therapeutics Reports Narrowed Losses - TipRanks
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories - StockTitan
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - StockTitan
This trade activity should not be overlooked: Cytokinetics Inc (CYTK) - SETE News
Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN
XTX Topco Ltd Makes New $889,000 Investment in Churchill Downs Incorporated (NASDAQ:CHDN) - MarketBeat
Renaissance Technologies LLC Takes Position in ChampionX Co. (NASDAQ:CHX) - MarketBeat
Tucows Inc. (NASDAQ:TCX) CEO Elliot Noss Sells 5,700 Shares of Stock - Defense World
622,616 Shares in ChampionX Co. (NASDAQ:CHX) Bought by Renaissance Technologies LLC - Defense World
Coherent (COHR) Soars 6.3%: Is Further Upside Left in the Stock? - Yahoo Finance
CTMX: A Tale of Ups & Downs – -48.46% loss in 6 Months, -5.65% in 30 Days - The InvestChronicle
Insider Selling: Landau Jeffrey B, CytomX Therapeutics Inc [CTMX] Chief Business Officer divested 4,181 shares - Knox Daily
Choreo LLC Purchases Shares of 23,033 Coty Inc. (NYSE:COTY) - Defense World
Top 2% Biotech Hits Slam Dunk On Bid To Edge Out Bristol, Cytokinetics - Investor's Business Daily
Coherent Corp (COHR)’s Market Momentum: Closing Strong at 80.98, Up 3.93 - The Dwinnex
Autolus Therapeutics (AUTL) Appoints Matthias Will as Chief Development Officer - StreetInsider.com
Analyzing CTMX’s price-to-book ratio for the last quarter - US Post News
Altamira Therapeutics prices up to $12M public offering - MSN
Keeping an Eye on CytomX Therapeutics Inc (CTMX) After Insider Trading Activity - Knox Daily
Check Out CytomX Therapeutics Inc (CTMX)’s Trade Data Rather Than the Analysts’ Views - SETE News
Gaining Ground: CytomX Therapeutics Inc (CTMX) Closes Lower at 1.23, Down -1.60 - The Dwinnex
HC Wainwright Reaffirms Neutral Rating for CytomX Therapeutics (NASDAQ:CTMX) - Defense World
CytomX Therapeutics (NASDAQ:CTMX) Earns Neutral Rating from HC Wainwright - MarketBeat
Acadian Asset Management LLC Acquires 37,739 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Candriam S.C.A. Invests $256,000 in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World
Market Watch Highlights: CytomX Therapeutics Inc (CTMX) Ends on an Upturn Note at 1.31 - The Dwinnex
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Cytomx Therapeutics Inc Stock (CTMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cytomx Therapeutics Inc Stock (CTMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Landau Jeffrey B | Chief Business Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
119,056 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
179,829 |
| BELVIN MARCIA | SVP, Chief Scientific Officer |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
175,648 |
| ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Option Exercise |
0.00 |
11,250 |
0 |
134,978 |
| ROWLAND LLOYD A | General Counsel |
Aug 20 '24 |
Sale |
1.23 |
4,181 |
5,139 |
130,797 |
| Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Option Exercise |
0.00 |
6,875 |
0 |
110,061 |
| Ogden Christopher | Chief Financial Officer |
Aug 20 '24 |
Sale |
1.23 |
1,984 |
2,439 |
108,077 |
| McCarthy Sean A. | CEO |
Aug 20 '24 |
Option Exercise |
0.00 |
37,500 |
0 |
671,749 |
| McCarthy Sean A. | CEO |
Aug 20 '24 |
Sale |
1.23 |
13,898 |
17,082 |
657,851 |
| McCarthy Sean A. | CEO |
Mar 26 '24 |
Option Exercise |
1.57 |
109,768 |
172,874 |
634,249 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):